Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

An Infographic Look At Trends In Korean Gene And Stem Cell Therapies

Executive Summary

South Korea has opened a new era with the recent granting of approval to the country's first gene therapy, for Kolon Life Science's osteoarthritis drug Invossa. (Also see "First Approval For Kolon's Invossa But No Disease-Modifying Status" - Scrip, 14 Jul, 2017.) Scrip takes a graphical look at the current state of the country's wider gene and stem cell therapy sector, one of the key biotech areas the government is nurturing.

Advertisement

Related Content

First Approval For Kolon's Invossa But No Disease-Modifying Status

Topics

Advertisement
UsernamePublicRestriction

Register

SC099147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel